Celsion Corporation Reports 2018 Financial Results
29 mars 2019 08h00 HE
|
Celsion CORP
Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline Company to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT ...
Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019
22 mars 2019 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, March 22, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended...
Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
04 mars 2019 08h30 HE
|
Celsion CORP
100% Objective Response Rates and 88% Complete (R0) Resection Rates in Highest Dose Cohorts GEN-1 Intraperitoneally Delivered Durable Local Levels of Pro-Immune IL-12 and Related Cytokines ...
Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium
15 janv. 2019 08h30 HE
|
Celsion CORP
Data to be Highlighted During Oral Session on March 2, 2019 LAWRENCEVILLE, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today...
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer
18 déc. 2018 08h00 HE
|
Celsion CORP
Current Combined, Blinded Progression-Free Survival (PFS) Rate for Both Treatment Arms Reaches 21.2 Months Compared to 19.8 Months for the Intent-To-Treat (ITT) Population in the HEAT Study Post-Hoc...
Celsion Receives $11.1 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
03 déc. 2018 09h15 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet Proceeds Equate to More Than $0.55 Per Share LAWRENCEVILLE, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an...
Celsion Strengthens Its Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for up to $10 Million in Non-Dilutive Funding
04 sept. 2018 08h30 HE
|
Celsion CORP
Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
Celsion Corporation Reports Second Quarter 2018 Financial Results and Provides Business Update
14 août 2018 08h30 HE
|
Celsion CORP
Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance Company to Hold...